Brief: Prothena Announces Bristol Myers Squibb Opt-In For Worldwide Rights Of Prx005
10/07/2023 22:32
July 10 (Reuters) - Prothena Corporation PLC PRTA.O :
* PROTHENA ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN FOR
WORLDWIDE
RIGHTS OF PRX005, A NOVEL ANTI-MTBR-TAU ANTIBODY
* PROTHENA CORPORATION PLC - TO RECEIVE $55 MILLION FROM
BRISTOL
MYERS SQUIBB FOR EXCLUSIVE WORLDWIDE LICENSE TO PRX005
* PROTHENA CORP -ALL PROGRAM UPDATES, INCLUDING RESULTS FROM
ONGOING & ANY FUTURE PRX005 CLINICAL STUDIES, TO BE REPORTED BY
BRISTOL MYERS GOING FORWARD
Source text for Eikon: ID:nBw8Lp1qVa
Further company coverage: PRTA.O
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment